Evidence map›Paper›PMID 25867649›Full record

ArticleBone marrow transplantation2015

JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications.

T Wittmann, N Horowitz, N Benyamini, I Henig, T Zuckerman, J M Rowe, Z Kra-Oz, M Szwarcwort Cohen, I Oren, I Avivi

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

T WittmannBruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
N Horowitz1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
N BenyaminiDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
I HenigDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
T Zuckerman1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
J M Rowe1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel [3] Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Z Kra-Oz1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Virology Laboratory, Rambam Health Care Campus, Haifa, Israel.
M Szwarcwort CohenVirology Laboratory, Rambam Health Care Campus, Haifa, Israel.
I Oren1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Unit of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
I Avivi1] Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel [2] Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel [3] Department of Hematology and Bone Marrow Transplantation, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extended application of allogeneic stem cell transplantation (alloSCT) is expected to increase the frequency of JC polyomavirus (JCPyV)-related progressive multifocal leukoencephalopathy (PML). The aim of this study was to assess frequency, risk factors and course of JCPyV reactivation in allografted hematology patients. This retrospective study included consecutive adult patients, treated with alloSCT between January 2008 and December 2011. Quantitative JCPyV-PCR analysis was performed on whole blood DNA samples, originally drawn for cytomegalovirus detection since transplant date. The study included 164 patients diagnosed with hematological malignancies. Patients received reduced-intensity conditioning (n=74) or myeloablative conditioning (n=90), followed by alloSCT. Twenty patients developed transient and 20 had persistent JCPyV reactivation. Two of the patients with persistent reactivation showed a gradual increase in JCPyV levels, preceding PML development by 96 and 127 days. Cessation of immunosuppression resulted in complete resolution of neurological symptoms in one patient, while the other died of PML. Seventy percent of the 'persistently reactivating' patients died. Multivariate analysis confirmed age to be the only significant predictive factor for JCPyV reactivation. In conclusion, JCPyV reactivation occurs in a quarter of allografted patients. Preemptive detection of JCPyV reactivation in high-risk subjects and early discontinuation of immunosuppressive therapy may prevent development of lethal PML.

Indexed as

AdolescentAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansJC VirusLeukoencephalopathy, Progressive MultifocalMaleMiddle AgedTransplantation, HomologousYoung Adult

Identifiers

PMID25867649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.